Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to $5 billion, as it looks to strengthen its cancer drugs pipeline.
This marks the latest in Gilead’s acquisition spree. The company has been expanding beyond its key areas for growth amid looming patent expiries and declining sales of its COVID-19 treatment.
In February, the U.S. drugmaker bought partner Arcellx for up to $7.8 billion, while last month it agreed to acquire privately held biotech firm Ouro Medicines in a deal worth more than $2 billion.
With the latest deal, Gilead will get access to Tubulis’ experimental drugs, which belong to a class called antibody-drug conjugates (ADC), popularly known as “guided missiles”, that deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue.
We believe the Tubulis acquisition represents a strategically sound bolt-on that addresses Gilead’s oncology pipeline growth needs, while securing differentiated next-gen ADC platform capabilities, said RBC Capital Markets analyst Brian Abrahams.
Tubulis’ lead asset, TUB-040, which binds to NaPi2b, a protein found in certain cancer cells, is currently in early-stage development for a type of ovarian cancer and non-small cell lung cancer.
Another experimental drug, TUB-030, is being studied across various solid tumor types.
“The agreement to acquire Tubulis is a significant milestone in Gilead’s progress in oncology,” said Gilead CEO Daniel O’Day.
Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash, payable at closing, and up to $1.85 billion in milestone payments.
Gilead’s shares slipped 1.4% in early trading.
The companies have previously entered into licensing agreements to develop ADCs. Tubulis also has a partnership with Bristol-Myers Squibb
Following the close of the transaction, expected in the second quarter of 2026, Tubulis will operate as an ADC research organization within Gilead.
Source: Economic Times